- Home
- IONS vs DY Comparison
IONS vs DY Comparison
Compare IONS & DY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- DY
- Stock Information
- Founded
- IONS 1989
- DY 1969
- Country
- IONS United States
- DY United States
- Employees
- IONS N/A
- DY N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- DY Water Sewer Pipeline Comm & Power Line Construction
- Sector
- IONS Health Care
- DY Industrials
- Exchange
- IONS Nasdaq
- DY Nasdaq
- Market Cap
- IONS 6.8B
- DY 5.3B
- IPO Year
- IONS 1991
- DY N/A
- Fundamental
- Price
- IONS $42.53
- DY $254.32
- Analyst Decision
- IONS Buy
- DY Strong Buy
- Analyst Count
- IONS 16
- DY 10
- Target Price
- IONS $58.25
- DY $236.10
- AVG Volume (30 Days)
- IONS 2.0M
- DY 309.2K
- Earning Date
- IONS 07-31-2025
- DY 08-20-2025
- Dividend Yield
- IONS N/A
- DY N/A
- EPS Growth
- IONS N/A
- DY 1.66
- EPS
- IONS N/A
- DY 7.89
- Revenue
- IONS $717,253,000.00
- DY $4,818,199,000.00
- Revenue This Year
- IONS $7.98
- DY $17.78
- Revenue Next Year
- IONS $16.09
- DY $7.78
- P/E Ratio
- IONS N/A
- DY $31.99
- Revenue Growth
- IONS N/A
- DY 12.77
- 52 Week Low
- IONS $23.95
- DY $131.37
- 52 Week High
- IONS $52.34
- DY $255.65
- Technical
- Relative Strength Index (RSI)
- IONS 63.92
- DY 71.85
- Support Level
- IONS $41.22
- DY $246.82
- Resistance Level
- IONS $42.95
- DY $255.42
- Average True Range (ATR)
- IONS 1.36
- DY 5.37
- MACD
- IONS 0.05
- DY -0.46
- Stochastic Oscillator
- IONS 70.80
- DY 87.23
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About DY Dycom Industries Inc.
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. Its operating companies supply telecommunications providers with a comprehensive portfolio of specialty services, including program management; planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services and provide underground facility locating services for various utilities, including telecommunications providers, and others. It also provides a range of construction, maintenance, and installation services, including the placement and splicing of fiber, copper, and coaxial cables. It provides services throughout the United States.